Aethlon Medical, Inc.
AEMDAethlon Medical, Inc. in brief
Aethlon Medical, Inc. is a listed company in the Medical Devices industry, based in San Diego, California, USA. It was founded in 1999. Its market value was $9 M on 30 October 2026, which makes it the 26,127th largest listed company in the world and the 4,326th largest in the USA on this site. It employs about 9 people and James B. Frakes is its chief executive. Its shares trade under the symbol AEMD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Aethlon Medical, Inc.
We are a medical therapeutic company focused on developing the Hemopurifier® (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases.
From the company's annual report filed with the US SEC: read the report
Aethlon Medical, Inc. timeline
- 1997
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1999
- 🏁Founded
- 2000
- ✎Renamed Aethlon Medical IncFormerly Bishop Equities Inc.
- 2020
- 💰Record revenue of $1 millionFY2020, the highest of the 5 years on record.
Events of Aethlon Medical, Inc. from SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,845 (Jan 2020) · #4,274 (Jan 2021) · #5,210 (Jan 2022) · #5,721 (Dec 2022) · #5,458 (Jul 2023) · #4,604 (Jan 2024) · #2,486 (Mar 2026) · #4,172 (Aug 2026) · #4,275 (Oct 2026) · #4,329 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.8×
- Free cash flow yield
- -78.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -146.2%
- Liabilities / assets
- 22.9%
- Revenue growth
- +96.6%
- R&D / revenue
- 480.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | — | — | $-7M | $-7M | — |
| Mar 2025 | — | — | $-9M | $-13M | — |
| Mar 2024 | — | — | $-13M | $-12M | — |
| Mar 2023 | $1M | +96.6% | $-12M | $-12M | -2110.5% |
| Mar 2022 | $0M | -56.1% | $-10M | $-10M | -3593.1% |
| Mar 2021 | $1M | +1.5% | $-8M | $-8M | -1195.5% |
| Mar 2020 | $1M | +182.6% | $-6M | $-6M | -980.0% |
| Mar 2019 | $0M | — | $-6M | $-6M | -2691.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-7M | $0M | $-7M | $-10.61 | — |
| Mar 2025 | $-8M | $0M | $-8M | $-85.77 | — |
| Mar 2024 | $-10M | $0M | $-10M | $-38.87 | — |
| Mar 2023 | $-11M | $1M | $-11M | $-5.86 | — |
| Mar 2022 | $-10M | $0M | $-10M | $-0.71 | — |
| Mar 2021 | $-7M | $0M | $-7M | $-0.65 | — |
| Mar 2020 | $-5M | $0M | $-5M | $-1.87 | — |
| Mar 2019 | $-4M | $0M | $-4M | $-5.13 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 9, 20268-KCurrent reportBylaws amended
- Oct 5, 20268-K/ACurrent report (amended)Shareholder vote
- Oct 1, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Sep 17, 20268-KCurrent reportMaterial agreement · Change in control · Regulation FD disclosure
- Sep 15, 20268-KCurrent reportDirectors or officers changed
- Sep 1, 2026DEF 14AProxy statement
- Aug 31, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 31, 20268-KCurrent reportBylaws amended
Official filings of Aethlon Medical, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-7 M
- Net income
- $-7 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $6 M
- Total liabilities
- $1 M
- Total equity
- $5 M
As of March-2026
Top 17 institutional investors in Aethlon Medical, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Stempoint Capital LP | 213,685 | New | 13.29% | $1 M | Nov 16, 2026 |
| 2 | Birchview Capital, LP | 62,837 | New | 3.91% | $0 M | Nov 13, 2026 |
| 3 | Shay Capital LLC | 62,249 | New | 3.87% | $0 M | Nov 16, 2026 |
| 4 | Diadema Partners LP | 50,000 | New | 3.11% | $0 M | Nov 16, 2026 |
| 5 | Schonfeld Strategic Advisors LLC | 25,769 | New | 1.60% | $0 M | Nov 16, 2026 |
| 6 | HRT Financial LP | 21,643 | New | 1.35% | $0 M | Nov 13, 2026 |
| 7 | Jane Street Group, LLC | 21,534 | New | 1.34% | $0 M | Nov 12, 2026 |
| 8 | StoneX Group Inc. | 14,861 | New | 0.92% | $0 M | Nov 3, 2026 |
| 9 | FNY Investment Advisers, LLC | 14,500 | New | 0.90% | $0 M | Oct 16, 2026 |
| 10 | Persistent Asset Partners Ltd | 12,700 | New | 0.79% | $0 M | Nov 13, 2026 |
| 11 | Level Four Advisory Services, LLC | 10,000 | New | 0.62% | $0 M | Nov 6, 2026 |
| 12 | Tower Research Capital LLC (TRC) | 2,620 | New | 0.16% | $0 M | Nov 16, 2026 |
| 13 | UBS Group AG | 2,605 | New | 0.16% | $0 M | Nov 10, 2026 |
| 14 | Morgan Stanley | 494 | New | 0.03% | $0 M | Nov 13, 2026 |
| 15 | Jones Financial Companies Lllp | 3 | New | 0.00% | $0 M | Nov 13, 2026 |
| 16 | BlackRock, Inc. | 3 | New | 0.00% | $0 M | Nov 13, 2026 |
| 17 | Group One Trading LLC | 2 | New | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Aethlon Medical, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 18,891 | $0 M | 1.2% | <0.01% | +185% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,077 | $0 M | 0.07% | <0.01% | +347% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aethlon Medical, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Steven P. LarosaChief Medical Officer | Grant or award | +42,000 | — | — | 42,057 | Form 4 |
| filed | James B. FrakesCFO/CEO, Director | Grant or award | +42,000 | — | — | 42,063 | Form 4 |
| filed | Nicolas GikakisDirector | Shares withheld for tax | -436 | $6.520 | $3 K | 3,784 | Form 4 |
| filed | Chetan ShahDirector | Shares withheld for tax | -436 | $6.520 | $3 K | 3,787 | Form 4 |
| filed | Edward G. BroennimanDirector | Shares withheld for tax | -218 | $6.520 | $1 K | 4,313 | Form 4 |
| filed | Chetan ShahDirector | Shares withheld for tax | -2,182 | $0.820 | $2 K | 20,840 | Form 4 |
| filed | Nicolas GikakisDirector | Shares withheld for tax | -2,182 | $0.820 | $2 K | 20,663 | Form 4 |
| filed | Edward G. BroennimanDirector | Shares withheld for tax | -1,091 | $0.820 | $895 | 22,363 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aethlon Medical, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-08-03 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-10-17 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-06-06 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 2,583 shares at $5.52
- : 8,535 shares at $5.55
- : 3,834 shares at $5.07
- : 26,311 shares at $5.15
- : 18,992 shares at $5.05
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aethlon Medical, Inc. scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.8×Price to book 1.8× against Medical Devices's median of 2.5×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-78.9%Free cash flow is -78.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-10.61 vs -85.77Diluted EPS -10.61 in fiscal 2025 against -85.77 the year before (report's currency).
- ✓Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$8 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-142.9%-142.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.84 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-729.0×Operating income -729.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year332.1%Diluted shares up 332.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Aethlon Medical, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | 0−100%— | 0.6+95.2%100% | 0.3−55.4%100% | 0.7+1.4%100% | 0.7+183%100% | 0.2+53.5%100% | 0.1−61.8%100% | 0.4—100% | |
| Research and development | 1.9−13.6%— | 2.2−12.2%— | 2.5−8.2%— | 2.7+17.3%478% | 2.3+13.0%796% | 2.1+124%314% | 0.9+3.5%143% | 0.9+52.9%390% | 0.6−12.9%392% | 0.7—172% | |
| General and administrative | 2.7−16.9%— | 3.2−16.9%— | 3.9−12.9%— | 4.5+29.7%780% | 3.5+40.6%1175% | 2.5r2.5+58.7%373% | 1.5+62.4%238% | 1.0+20.3%415% | 0.8−6.7%530% | 0.8—217% | |
| Operating expenses | 7.3−21.9%— | 9.3−26.1%— | 13+1.3%— | 12+16.4%2172% | 11+25.3%3643% | 8.6r8.5+29.9%1297% | 6.6+5.6%1012% | 6.2+25.1%2713% | 5.0−23.3%3329% | 6.5—1655% | |
| Operating income | −7.3—— | −9.3—— | −13—— | −12—−2072% | −10—−3543% | −7.9r−7.9—−1197% | −5.9—−912% | −6.0—−2613% | −4.8—−3229% | −6.1—−1555% | |
| Interest and finance income | 0.2−47.5%— | 0.3—— | — | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.0+42.2%— | 0.0—— | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.1—— | −4.0—— | — | — | — | −0.0—−0.2% | −0.5—−69.2% | −0.2—−96.0% | — | — | |
| Income before tax | −7.2—— | −13—— | — | — | — | — | — | — | — | — | |
| Income tax | 0—— | 0—— | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | — | — | — | −12—−2095% | −10—−3543% | −7.9—−1197% | −6.4—−981% | −6.2—−2709% | −5.7—−3809% | −7.3—−1864% | |
| Minority interests' share of net income | — | — | — | 0—0.0% | −0.0—−1.6% | −0.0—−0.7% | −0.0—−0.9% | −0.0—−10.8% | −0.0—−13.6% | −0.0—−7.8% | |
| Net income attributable to shareholders | −7.2—— | −13—— | −12—— | −12—−2095% | −10—−3541% | −7.9—−1197% | −6.4—−980% | −6.2—−2698% | −5.7—−3796% | −7.3—−1856% | |
| Earnings per share, basic | -10.61—— | -85.77r-8.58—— | -38.87r-4.86—— | -5.86r-0.59—— | -0.71—— | -0.65—— | -1.87—— | -5.13r-0.07—— | -0.10r-0.46—— | -0.94—— | |
| Earnings per share, diluted | -10.61—— | -85.77r-8.58—— | -38.87r-4.86—— | -5.86r-0.59—— | -0.71—— | -0.65—— | -1.87—— | -5.13r-0.07—— | -0.10r-0.46—— | -0.94—— | |
| Shares, weighted average (basic) | 0.7+332%— | 0.2r1.6−50.3%— | 0.3r2.5−84.7%— | 2.1r21−86.1%— | 15—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 0.7+332%— | 0.2r1.6−50.3%— | 0.3r2.5−84.7%— | 2.1r21−86.1%— | 15+22.1%— | 12+254%— | 3.4+183%— | 1.2r18−90.2%— | 12+58.6%— | 7.8—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.0−8.6%79.4% | 5.5+1.1%74.8% | 5.4−62.6%66.0% | 15−14.9%83.0% | 17+73.1%87.9% | 9.9+2.7%92.4% | 9.6r9.6+151%92.5% | 3.8−45.1%92.8% | 7.0+347%94.9% | 1.6—90.3% | |
| Receivables | — | — | — | 0−100%0.0% | 0.1−14.2%0.7% | 0.1−27.9%1.4% | 0.2—2.0% | 0−100%0.0% | 0.1—1.0% | 0—0.0% | |
| Other current assets | 0.3−26.0%5.2% | 0.4−11.4%6.1% | 0.5−9.3%6.1% | 0.6−41.7%3.2% | 1.0+180%4.9% | 0.3+48.6%3.2% | 0.2+9.3%2.2% | 0.2+15.8%5.1% | 0.2+383%2.5% | 0.0—2.2% | |
| Current assets | 5.6−6.4%87.9% | 5.9−4.4%80.8% | 6.2−58.7%75.5% | 15−16.9%86.2% | 18+75.4%93.5% | 10+3.1%97.0% | 10+149%96.7% | 4.0−44.1%97.9% | 7.2+353%98.3% | 1.6—92.5% | |
| Property, plant and equipment | 0.4−47.2%5.6% | 0.7−33.4%9.2% | 1.0−11.3%12.3% | 1.1+159%6.5% | 0.4+174%2.3% | 0.2+14.6%1.5% | 0.1+2233%1.4% | 0.0−78.1%0.1% | 0.0−5.7%0.4% | 0.0—1.7% | |
| Right-of-use (leased) assets | 0.3−48.9%4.9% | 0.6−31.8%8.2% | 0.9−23.3%10.7% | 1.2+65.3%6.6% | 0.7+1626%3.6% | 0.0−70.4%0.4% | 0.1—1.3% | 0—0.0% | — | — | |
| Other intangible assets | 0−100%0.0% | 0.0−50.0%0.0% | 0.0−33.3%0.0% | 0.0−25.0%0.0% | 0.0−96.1%0.0% | 0.1−1.0%0.5% | 0.1−13.7%0.6% | 0.1−12.1%1.6% | 0.1−10.8%1.0% | 0.1—4.9% | |
| Total assets | 6.3−13.9%100% | 7.4−10.8%100% | 8.2−52.9%100% | 18−9.8%100% | 19+82.0%100% | 11+2.7%100% | 10+152%100% | 4.1−43.9%100% | 7.4+326%100% | 1.7—100% | |
| Accounts payable | 0.4−28.1%6.1% | 0.5−31.3%7.3% | 0.8+79.7%9.4% | 0.4r0.4−13.4%2.5% | 0.5+48.1%2.6% | 0.3+18.5%3.2% | 0.3+116%2.7% | 0.1+6.0%3.2% | 0.1−74.3%1.7% | 0.5—28.1% | |
| Current liabilities | 1.4−23.8%22.8% | 1.9+3.8%25.8% | 1.8+21.6%22.2% | 1.5r1.5−17.5%8.6% | 1.8+32.6%9.4% | 1.4+28.8%12.9% | 1.1−41.5%10.3% | 1.8+282%44.2% | 0.5−21.9%6.5% | 0.6—35.4% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.3−48.2%4.6% | 0.6−30.9%7.9% | 0.9+56.0%5.4% | 0.6—3.1% | 0−100%0.0% | 0.0—0.4% | 0—0.0% | — | — | |
| Total liabilities | 1.4−35.3%22.8% | 2.2−9.8%30.4% | 2.5+1.4%30.1% | 2.4r2.4+0.7%14.0% | 2.4+76.4%12.5% | 1.4+23.9%12.9% | 1.1−39.1%10.7% | 1.8+38.3%44.2% | 1.3+16.6%17.9% | 1.1—65.5% | |
| Retained earnings | −175—−2765% | −168—−2282% | −155—−1874% | −142r−142—−813% | −130—−671% | −120—−1124% | −112—−1078% | −106—−2563% | −99—−1353% | −94—−5432% | |
| Shareholders' equity | 4.9−4.6%77.2% | 5.1−11.1%69.6% | 5.8−61.7%69.9% | 15r15−11.3%86.0% | 17r17+80.2%87.5% | 9.4+0.2%88.4% | 9.4+288%90.6% | 2.4−60.5%58.8% | 6.1+807%83.4% | 0.7—39.2% | |
| Minority interests | — | — | — | 0—0.0% | −0.1—−0.7% | −0.1—−1.3% | −0.1—−1.3% | −0.1—−3.1% | −0.1—−1.4% | −0.1—−4.7% | |
| Total equity | — | — | 5.8−61.7%69.9% | 15r15−11.3%86.0% | 17+82.8%87.5% | 9.3+0.2%87.1% | 9.3+304%89.3% | 2.3−61.9%55.8% | 6.0+913%82.1% | 0.6—34.5% | |
| Total liabilities and equity | 6.3−13.9%100% | 7.4−10.8%100% | 8.2−52.9%100% | 18−9.8%100% | 19+82.0%100% | 11+2.7%100% | 10+152%100% | 4.1−43.9%100% | 7.4+326%100% | 1.7—100% | |
| Shares outstanding | 0.3r1.6+56.2%— | 0.2r2.0−38.8%— | 0.3r2.6−85.7%— | 2.3r23−85.1%— | 150.0%— | 15r12+64.6%— | 9.4r9.4+639%— | 1.3r19−92.9%— | 18+102%— | 8.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.3−4.7%— | 0.3−5.4%— | 0.4+49.1%— | 0.2+94.8%41.9% | 0.1+210%42.0% | 0.0+51.5%6.1% | 0.0−14.1%4.1% | 0.0−13.9%13.4% | 0.0+10.0%23.8% | 0.0—8.3% | |
| Share-based compensation | 0.3−32.9%— | 0.4−65.9%— | 1.2+15.9%— | 1.1+40.1%183% | 0.8−3.7%255% | 0.8−7.7%118% | 0.8−36.0%130% | 1.3+4.6%574% | 1.3−42.3%843% | 2.2—558% | |
| Cash from operating activities | −7.0—— | −7.6—— | −10—— | −11—−1829% | −9.8—−3320% | −6.8—−1026% | −5.2—−799% | −4.3—−1870% | −3.9—−2614% | −3.5—−894% | |
| Capital expenditure | −0.0—— | 0—— | −0.3—— | −0.9—−164% | −0.3—−119% | −0.1—−9.1% | −0.2—−23.3% | 0—0.0% | −0.0—−16.6% | −0.0—−4.2% | |
| Cash from investing activities | −0.0—— | 0—— | −0.3—— | −0.9—−164% | −0.3—−119% | −0.1—−9.1% | −0.2—−23.3% | 0—0.0% | −0.0—−16.6% | −0.0—−4.2% | |
| Shares issued | 6.9+46.7%— | 4.7r3.5+256%— | 1.3−85.2%— | 8.9—1555% | — | — | — | — | — | — | |
| Cash from financing activities | 6.5−15.6%— | 7.7+500%— | 1.3−85.6%— | 8.9−48.7%1552% | 17+144%5904% | 7.1−35.9%1082% | 11+870%1711% | 1.1−87.7%500% | 9.3+216%6249% | 3.0—755% | |
| Exchange-rate effect on cash | 0.0—— | −0.0−682%— | 0.0—— | −0.0—−1.0% | 0—0.0% | — | — | — | — | — | |
| Change in cash | −0.5−781%— | 0.1—— | −9.1—— | −2.5r−2.5−135%−442% | 7.3—2465% | — | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 2.2−9.8%— | 0.5+63.6%— | 0.5+4.8%— | 0.6*−55.6%— | 0.5+122%— | 0.3r0.3+12.4%— | 0.5r0.5+26.4%— | 1.3*+106%— | 0.2−59.5%— | 0.3—— | 0.4—— | 0.6*—— | 0.6—— | |
| General and administrative | 2.8−0.2%— | 0.7+30.9%— | 0.7−9.9%— | 0.7*−2.8%— | 0.7−9.2%— | 0.5−45.6%— | 0.7−2.2%— | 0.7*−6.1%— | 0.8−16.6%— | 1.0—— | 0.8—— | 0.8*—— | 1.0—— | |
| Operating expenses | 8.2+15.8%— | 2.7+77.2%— | 1.6−11.9%— | 1.9*−3.7%— | 2.1+13.6%— | 1.5−48.0%— | 1.8−31.6%— | 2.0*−19.4%— | 1.8−49.1%— | 2.9—— | 2.6—— | 2.5*—— | 3.6—— | |
| Operating income | −8.2—— | −2.7—— | −1.6—— | −1.9*—— | −2.1—— | −1.5—— | −1.8—— | −2.0*—— | −1.8—— | −2.9—— | −2.6—— | −2.5*—— | −3.6—— | |
| Net interest income | — | 0.1+138%— | 0.0+2.5%— | — | 0.0−26.8%— | 0.0−76.1%— | 0.0—— | — | 0.1—— | 0.1—— | — | — | — | |
| Other non-operating income (expense) | — | — | — | — | — | — | −0.0—— | — | — | — | 0—— | — | — | |
| Net income including minority interests | — | — | — | — | −2.0*—— | — | — | — | −1.8*—— | −2.8—— | −2.6—— | — | −3.5—— | |
| Net income attributable to shareholders | −8.1—— | −2.6—— | −1.5—— | −1.9*—— | −2.0—— | −1.5—— | −1.8—— | −6.3*—— | −1.8—— | −2.8—— | −2.6—— | −2.4*—— | −3.5—— | |
| Earnings per share, basic | — | -2.60—— | -4.02—— | — | -2.45—— | -18.70r-3.74—— | -42.42r-0.85—— | — | -10.05r-0.13—— | -16.11r-0.20—— | -2.76r-0.34—— | — | -1.37—— | |
| Earnings per share, diluted | — | -2.60—— | -4.02—— | — | -2.45—— | -18.70r-3.74—— | -42.42r-0.85—— | — | -10.05r-0.13—— | -16.11r-0.20—— | -2.76r-0.34—— | — | -1.37—— | |
| Shares, weighted average (basic) | 1.0+1167%— | 1.0+1167%— | 0.4+826%— | — | 0.8+372%— | 0.1r0.4−54.4%— | 0.0r2.1−95.5%— | — | 0.2r14−93.1%— | 0.2r14—— | 0.9r7.5—— | — | 2.5—— | |
| Shares, weighted average (diluted) | 1.0+1167%— | 1.0+1167%— | 0.4+826%— | — | 0.8+372%— | 0.1r0.4−54.4%— | 0.0r2.1−95.5%— | — | 0.2r14−93.1%— | 0.2r14—— | 0.9r7.5—— | — | 2.5—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.5—88.5% | 6.5+10.8%88.5% | 4.9+31.0%79.1% | 5.0−8.6%79.4% | 7.0+44.2%86.3% | 5.9−14.7%79.9% | 3.8−58.5%71.0% | 5.5+1.1%74.8% | 4.8−39.5%73.9% | 6.9—77.5% | 9.1—79.5% | 5.4—66.0% | 8.0—76.4% | |
| Other current assets | 0.2—2.3% | 0.2−7.6%2.3% | 0.3+2.4%4.5% | 0.3−26.0%5.2% | 0.2+110%2.3% | 0.2−34.7%2.5% | 0.3−42.1%5.2% | 0.4−11.4%6.1% | 0.1−68.2%1.4% | 0.3—3.2% | 0.5—4.2% | 0.5—6.1% | 0.3—2.7% | |
| Current assets | 6.9—93.6% | 6.9+9.7%93.6% | 5.6+38.5%90.0% | 5.6−6.4%87.9% | 7.1+43.7%88.6% | 6.3−12.4%85.4% | 4.1−57.6%76.3% | 5.9−4.4%80.8% | 5.0−39.8%76.1% | 7.1—80.7% | 9.6—83.7% | 6.2—75.5% | 8.2—79.0% | |
| Property, plant and equipment | 0.2—2.9% | 0.2−58.1%2.9% | 0.3−50.6%4.7% | 0.4−47.2%5.6% | 0.4−43.0%5.4% | 0.5−39.1%7.0% | 0.6−36.1%11.2% | 0.7−33.4%9.2% | 0.8−31.6%11.7% | 0.8—9.5% | 0.9—8.1% | 1.0—12.3% | 1.1—10.7% | |
| Right-of-use (leased) assets | 0.2—2.1% | 0.2−65.9%2.1% | 0.2−56.2%3.7% | 0.3−48.9%4.9% | 0.4−43.2%4.7% | 0.5−38.6%6.2% | 0.5−34.9%10.0% | 0.6−31.8%8.2% | 0.7−29.2%10.3% | 0.7—8.4% | 0.8—7.1% | 0.9—10.7% | 1.0—9.1% | |
| Other intangible assets | — | — | — | 0−100%0.0% | 0.0−79.9%0.0% | 0.0−66.7%0.0% | 0.0−57.1%0.0% | 0.0−50.0%0.0% | 0.0−44.4%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Total assets | 7.3—100% | 7.3+0.1%100% | 6.2+17.5%100% | 6.3−13.9%100% | 8.1+23.5%100% | 7.3−17.2%100% | 5.3−53.5%100% | 7.4−10.8%100% | 6.5−37.5%100% | 8.8—100% | 11—100% | 8.2—100% | 10—100% | |
| Accounts payable | 0.7—10.1% | 0.7+30.3%10.1% | 0.4−28.0%6.6% | 0.4−28.1%6.1% | 0.5−23.2%5.8% | 0.6−38.2%7.8% | 0.6−46.5%10.8% | 0.5−31.3%7.3% | 0.6−11.9%9.4% | 0.9—10.4% | 1.1—9.4% | 0.8—9.4% | 0.7—6.6% | |
| Current liabilities | 1.3—17.4% | 1.3−9.0%17.4% | 1.0−36.3%16.6% | 1.4−23.8%22.8% | 1.3−29.1%15.6% | 1.4−39.7%19.2% | 1.6−23.6%30.7% | 1.9+3.8%25.8% | 1.8−15.6%27.2% | 2.3—26.4% | 2.1—18.6% | 1.8—22.2% | 2.1—20.1% | |
| Lease liabilities (non-current) | — | — | — | 0−100%0.0% | 0.1−79.2%1.1% | 0.2−65.4%2.4% | 0.3−55.6%4.8% | 0.3−48.2%4.6% | 0.4−42.4%6.4% | 0.5—5.6% | 0.6—5.0% | 0.6—7.9% | 0.7—6.9% | |
| Total liabilities | — | — | — | 1.4−35.3%22.8% | 1.3−38.7%16.7% | 1.6−44.2%21.5% | 1.9−30.4%35.5% | 2.2−9.8%30.4% | 2.2−22.4%33.6% | 2.8—32.0% | 2.7—23.7% | 2.5—30.1% | 2.8—27.1% | |
| Retained earnings | −179—−2445% | −179—−2445% | −177—−2833% | −175—−2765% | −173—−2150% | −171—−2338% | −170—−3199% | −168—−2282% | −162—−2478% | −160—−1808% | −157—−1377% | −155—−1874% | −152—−1458% | |
| Shareholders' equity | 6.1—82.6% | 6.1+5.3%82.6% | 5.2+51.9%83.4% | 4.9−4.6%77.2% | 6.7+54.9%83.3% | 5.7−4.5%78.5% | 3.4−60.7%64.5% | 5.1−11.1%69.6% | 4.3−43.1%66.4% | 6.0—68.0% | 8.7—76.3% | 5.8—69.9% | 7.6—72.9% | |
| Total equity | — | — | — | — | — | — | — | — | — | — | — | 5.8—69.9% | — | |
| Total liabilities and equity | 7.3—100% | 7.3+0.1%100% | 6.2+17.5%100% | 6.3−13.9%100% | 8.1+23.5%100% | 7.3−17.2%100% | 5.3−53.5%100% | 7.4−10.8%100% | 6.5−37.5%100% | 8.8—100% | 11—100% | 8.2—100% | 10—100% | |
| Shares outstanding | 1.6—— | 1.6+111%— | 0.5−81.6%— | 0.3r1.6+56.2%— | 1.0−93.0%— | 0.8−94.5%— | 2.6−81.4%— | 0.2r2.0−38.8%— | 14+439%— | 14—— | 14—— | 0.3r2.6—— | 2.6—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.3−4.9%— | 0.1*+0.4%— | 0.1−11.8%— | 0.1*−5.1%— | 0.1*−2.6%— | 0.1*−6.9%— | 0.1−4.0%— | 0.1*−2.3%— | 0.1*−8.4%— | 0.1*—— | 0.1—— | 0.1*—— | 0.1*—— | |
| Share-based compensation | 0.2−24.0%— | 0.1−31.0%— | 0.1−31.0%— | 0.1*−15.5%— | 0.1−19.5%— | 0.1−36.2%— | 0.1−48.0%— | 0.1*−47.9%— | 0.1−84.3%— | 0.1—— | 0.1—— | 0.1*—— | 0.6—— | |
| Cash from operating activities | −7.3—— | −1.7*—— | −1.9—— | −1.8*—— | −1.9*—— | −1.7*—— | −1.7—— | −1.7*—— | −2.0*—— | −2.2*—— | −1.7—— | −2.6*—— | −2.4*—— | |
| Capital expenditure | — | −0.0*—— | −0.0—— | — | — | 0*—— | 0—— | — | −0.0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | |
| Cash from investing activities | −0.0—— | −0.0*—— | −0.0—— | −0.0*−194%— | −0.0*—— | 0*—— | 0—— | 0.0*—— | −0.0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | |
| Shares issued | 6.4+13.0%— | 2.1*−53.4%— | 1.9—— | −0.8*—— | 3.2r4.0*+76.2%— | 4.5r3.7*—— | 0−100%— | −0.7r−1.8*−1468%— | 1.8r0*+889%— | 0r1.8*—— | 3.5—— | 0.0*—— | 0.2*—— | |
| Cash from financing activities | 7.9+29.7%— | 3.3*−12.0%— | 1.8—— | −0.2*−108%— | 3.0*—— | 3.7*—— | −0.0−100%— | 2.4*+5441%— | −0.0*−104%— | −0.0*—— | 5.4—— | 0.0*—— | 0.2*—— | |
| Exchange-rate effect on cash | 0.0—— | −0.0*−126%— | −0.0—— | 0.0*—— | −0.0*—— | 0.0*+22.9%— | −0.0—— | −0.0*—— | −0.0*−343%— | 0.0*—— | −0.0—— | −0.0*—— | 0.0*—— | |
| Change in cash | 0.6—— | 1.6*−25.6%— | −0.1—— | −1.9*−381%— | 1.1*—— | 2.1*—— | −1.7−148%— | 0.7*—— | −2.0*—— | −2.2*—— | 3.6—— | −2.5*—— | −2.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Aethlon Medical, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026James B. Frakes | $827 K | $827 K | $402 K | $1 |
| 2025James B. Frakes | $500 K | $495 K | $438 K | $9 |
| 2024James B. Frakes | $505 K | $395 K | $404 K | $44 |
Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026
Events at Aethlon Medical, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Change in control 1 · Directors and officers 3 · Material agreement 5 · Shareholder rights changed 3 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K/A | |
| Directors and officersShareholder vote | 8-K | |
| Change in controlMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2025 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Jan 2020 | $3 M | Private placement after listing | $2 to $10 million | 7 | options | SEC |
| Jun 2015 | $6 M | Private placement after listing | $2 to $10 million | 19 | equity, options | SEC |
| Dec 2014 | $3 M | Private placement after listing | $2 to $10 million | 4 | equity, options | SEC |
| Oct 2013 | $2 M | Private placement after listing | Under $2 million | 22 | equity, options | SEC |
| Jun 2012 | $2 M | No. 2 | $2 to $10 million | 27 | equity, options | SEC |
| Nov 2011 | $1 M | No. 1 | Under $2 million | 10 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Aethlon Medical, Inc. compares in Medical Devices
- Market cap$9 M · higher than 4% of 142
- Revenue growth96.5% · higher than 95% of 104
- Price / book1.8× · lower than 66% of 99
- FCF yield-78.9% · higher than 7% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aethlon Medical, Inc.🇺🇸 | $9 M | — | — | +96.5% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Employees:
- As of June 8, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aethlon Medical, Inc.? Verify and update this profile — free
Show Aethlon Medical, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.